The differential diagnosis of neovascular age-related macular degeneration (NVAMD) has practical implications because type 1 neovascularization (NV) with or without polypoidal components, type 2 NV, and type 3 NV (also called “retinal angiomatous proliferation”), differ in regard to visual prognosis, propensity for development of geographic atrophy, as well as frequency of antiangiogenic treatment and optimal dosing strategies. In many instances, only a combination of various imaging techniques facilitates the distinction between NVAMD variants, thereby permitting individualized therapy. Ideally, this allows for the use of a minimum number of treatments to achieve an anatomically and visually optimal outcome.
